Antismoking and potential antipsychotic effects of varenicline in subjects with schizophrenia or schizoaffective disorder: A double-blind placebo and bupropion-controlled study

S H Fatemi; Mahtab K. Yousefi; Rachel E. Kneeland; Stephanie B. Liesch; Timothy D. Folsom; Paul D. Thuras

doi:10.1016/j.schres.2013.02.015

Antismoking and potential antipsychotic effects of varenicline in subjects with schizophrenia or schizoaffective disorder: A double-blind placebo and bupropion-controlled study

S H Fatemi, Mahtab K. Yousefi, Rachel E. Kneeland, Stephanie B. Liesch, Timothy D. Folsom, Paul D. Thuras

Psychiatry & Behavioral Sciences

Research output: Contribution to journal › Letter › peer-review

25 Scopus citations

Original language	English (US)
Pages (from-to)	376-378
Number of pages	3
Journal	Schizophrenia Research
Volume	146
Issue number	1-3
DOIs	https://doi.org/10.1016/j.schres.2013.02.015
State	Published - May 2013

Bibliographical note

Funding Information:
Grant support from the National Institute on Drug Abuse (grant # R01DA024674-01A1 ) to SHF is gratefully acknowledged. We would like to thank all the participants in this clinical trial; Dr. Darlette Luke of the University of Minnesota Medical Center, Fairview Compounding Pharmacy for her assistance in dispensing medication and in the randomization of patients and Dr. Michael Kotlyar from the University of Minnesota College of Pharmacy for helpful comments. Pfizer provided free samples of varenicline and placebo and had no role in design or conduct of this study. Watson Laboratories provided free samples of Bupropion SR. All authors have no conflict of interest to declare.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1016/j.schres.2013.02.015

Find It

Find It at U of M Libraries

Cite this

Antismoking and potential antipsychotic effects of varenicline in subjects with schizophrenia or schizoaffective disorder: A double-blind placebo and bupropion-controlled study. / Fatemi, S H; Yousefi, Mahtab K.; Kneeland, Rachel E. et al.
In: Schizophrenia Research, Vol. 146, No. 1-3, 05.2013, p. 376-378.

Research output: Contribution to journal › Letter › peer-review

@article{12a3e72ec6be46148f61b4aafc1a780b,

title = "Antismoking and potential antipsychotic effects of varenicline in subjects with schizophrenia or schizoaffective disorder: A double-blind placebo and bupropion-controlled study",

author = "Fatemi, {S H} and Yousefi, {Mahtab K.} and Kneeland, {Rachel E.} and Liesch, {Stephanie B.} and Folsom, {Timothy D.} and Thuras, {Paul D.}",

note = "Funding Information: Grant support from the National Institute on Drug Abuse (grant # R01DA024674-01A1 ) to SHF is gratefully acknowledged. We would like to thank all the participants in this clinical trial; Dr. Darlette Luke of the University of Minnesota Medical Center, Fairview Compounding Pharmacy for her assistance in dispensing medication and in the randomization of patients and Dr. Michael Kotlyar from the University of Minnesota College of Pharmacy for helpful comments. Pfizer provided free samples of varenicline and placebo and had no role in design or conduct of this study. Watson Laboratories provided free samples of Bupropion SR. All authors have no conflict of interest to declare. ",

year = "2013",

month = may,

doi = "10.1016/j.schres.2013.02.015",

language = "English (US)",

volume = "146",

pages = "376--378",

journal = "Schizophrenia Research",

issn = "0920-9964",

publisher = "Elsevier",

number = "1-3",

}

TY - JOUR

T1 - Antismoking and potential antipsychotic effects of varenicline in subjects with schizophrenia or schizoaffective disorder

T2 - A double-blind placebo and bupropion-controlled study

AU - Fatemi, S H

AU - Yousefi, Mahtab K.

AU - Kneeland, Rachel E.

AU - Liesch, Stephanie B.

AU - Folsom, Timothy D.

AU - Thuras, Paul D.

N1 - Funding Information: Grant support from the National Institute on Drug Abuse (grant # R01DA024674-01A1 ) to SHF is gratefully acknowledged. We would like to thank all the participants in this clinical trial; Dr. Darlette Luke of the University of Minnesota Medical Center, Fairview Compounding Pharmacy for her assistance in dispensing medication and in the randomization of patients and Dr. Michael Kotlyar from the University of Minnesota College of Pharmacy for helpful comments. Pfizer provided free samples of varenicline and placebo and had no role in design or conduct of this study. Watson Laboratories provided free samples of Bupropion SR. All authors have no conflict of interest to declare.

PY - 2013/5

Y1 - 2013/5

UR - http://www.scopus.com/inward/record.url?scp=84875936380&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875936380&partnerID=8YFLogxK

U2 - 10.1016/j.schres.2013.02.015

DO - 10.1016/j.schres.2013.02.015

M3 - Letter

C2 - 23507358

AN - SCOPUS:84875936380

SN - 0920-9964

VL - 146

SP - 376

EP - 378

JO - Schizophrenia Research

JF - Schizophrenia Research

IS - 1-3

ER -

Antismoking and potential antipsychotic effects of varenicline in subjects with schizophrenia or schizoaffective disorder: A double-blind placebo and bupropion-controlled study

Bibliographical note

UN SDGs

Publisher link

Find It

Other files and links

Cite this